Intrinsiqs

Is Novo Nordisk A/S overvalued?

Novo Nordisk A/S (NVO) looks undervalued — trading about 69% below its fair value.

Undervalued
Current price $50.43 Fair value $85.23
Price
$50.43
Fair value
$85.23
Current P/E
12.5
Normal P/E
21.1
Market cap
$224.10B
Dividend yield
3.6%
Return on equity
52.8%
Sector
Healthcare

See the full interactive analysis →

Fair value compares NVO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 4 Jul 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.UNH UnitedHealth Group IncorporatedRHHBY Roche Holding AGMRK Merck & Co., Inc.